Agenus Inc AGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $8.15
- Day Range
- $6.43–9.22
- 52-Week Range
- $6.43–42.60
- Bid/Ask
- $6.51 / $6.51
- Market Cap
- $136.15 Mil
- Volume/Avg
- 1.5 Mil / 577,519
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.02
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 389
- Website
- https://www.agenusbio.com
Comparables
Valuation
|
Metric
|
AGEN
|
XNCR
|
STRO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 1.85 | 1.79 |
Price/Sales | 1.02 | 7.29 | 1.72 |
Price/Cash Flow | — | — | — |
Price/Earnings
AGEN
XNCR
STRO
Financial Strength
|
Metric
|
AGEN
|
XNCR
|
STRO
|
|---|---|---|---|
Quick Ratio | 0.40 | 7.14 | 4.39 |
Current Ratio | 0.44 | 7.36 | 4.50 |
Interest Coverage | −1.63 | — | −3.34 |
Quick Ratio
AGEN
XNCR
STRO
Profitability
|
Metric
|
AGEN
|
XNCR
|
STRO
|
|---|---|---|---|
Return on Assets (Normalized) | −63.60% | −9.75% | −22.26% |
Return on Equity (Normalized) | — | −11.83% | −57.95% |
Return on Invested Capital (Normalized) | — | −12.77% | −42.52% |
Return on Assets
AGEN
XNCR
STRO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ylctfvsyy | Kbsly | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gynfgnss | Fhvwql | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ynnfxsjf | Qrsdch | $98.6 Bil | |
MRNA
| Moderna Inc | Bzwvjflrx | Bldg | $41.0 Bil | |
ARGX
| argenx SE ADR | Rzcygrhl | Yvl | $22.4 Bil | |
BNTX
| BioNTech SE ADR | Ctgkyjgt | Jyq | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qsvbpndz | Ppnhldd | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kwykqjdjl | Lybkdh | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wqfhdnwcrx | Yttsrhc | $12.6 Bil | |
INCY
| Incyte Corp | Lcjncfx | Cygfmp | $12.0 Bil |